Nexalis Therapeutics (ASX:NX1) 3-1 Month Momentum %: -52.17% (As of Aug. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Nexalis Therapeutics 3-1 Month Momentum %?

Nexalis Therapeutics ASX:NX1 3-1 Month Momentum % is -52.17% as of Aug. 31, 2026. The stock has 3 warning signs investors should review. Among 1,385 Biotechnology companies, Nexalis Therapeutics ranks worse than 94.73% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-31), Nexalis Therapeutics's 3-1 Month Momentum % is -52.17%.

The industry rank for Nexalis Therapeutics's 3-1 Month Momentum % or its related term are showing as below:

ASX:NX1's 3-1 Month Momentum % is ranked worse than
94.73% of 1385 companies
in the Biotechnology industry
Industry Median: -9.14 vs ASX:NX1: -52.17

Nexalis Therapeutics  (ASX:NX1) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Nexalis Therapeutics 3-1 Month Momentum % Related Terms

ASX:NX1 vs VRTX, REGN, MRNA: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Nexalis Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nexalis Therapeutics 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nexalis Therapeutics's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Nexalis Therapeutics's 3-1 Month Momentum % falls into.


Nexalis Therapeutics  (ASX:NX1) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of -52.17% mean?
Nexalis Therapeutics (ASX:NX1) has a 3-1 Month Momentum % of -52.17% as of Aug. 31, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Nexalis Therapeutics and its competitors. According to the industry distribution chart, Nexalis Therapeutics ranks #1312 out of 1385 companies in the Biotechnology industry, placing it in the top 94.7%.
Is Nexalis Therapeutics' 3-1 Month Momentum % too high?
Nexalis Therapeutics' current 3-1 Month Momentum % is -52.17%. Based on the distribution chart, Nexalis Therapeutics ranks #1312 out of 1385 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Nexalis Therapeutics' 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nexalis Therapeutics ranks #1312 out of 1385 companies for 3-1 Month Momentum %. This places Nexalis Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Nexalis Therapeutics and its competitors. Nexalis Therapeutics's current 3-1 Month Momentum % is -52.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexalis Therapeutics stock overvalued right now?
Nexalis Therapeutics (ASX:NX1) has a current 3-1 Month Momentum % of -52.17%. The current 3-1 Month Momentum % is -52.17%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Nexalis Therapeutics (ASX:NX1), the current 3-1 Month Momentum % is -52.17% as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nexalis Therapeutics Business Description

Address 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Nexalis Therapeutics Ltd is an Australian clinical-stage drug development company that is focused on developing therapies to address unmet medical needs in pain management and mental health sectors. Its pipeline includes three clinical drug candidates focused on treatment-resistant depression (SRX-25), breakthrough cancer pain (IRX-211), and panic disorder (IRX-616a), each addressing areas of unmet medical need and potential commercial demand.